Pipeline :: CytoDyn Inc. (CYDY)

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
Colorectal Cancer	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
TNBC - Clinical Program	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
TNBC - MOA and combination studies	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
Glioblastoma	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
Chronic Inflammation	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
MASH	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
Leronlimab to prevent and/or reverse liver fibrosis	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
Alzheimer’s Disease	Pre-clinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started
Acute COVID-19	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
Long COVID	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
Antiviral therapy	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase complete	Phase 3 Phase in progress
Stem cell transplantation for HIV cure	Pre-clinical Phase complete	Phase 1 Phase complete	Phase 2 Phase in progress	Phase 3 Phase not started
Post-exposure prophylaxis	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started

Long-acting Leronlimab

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
	Pre-clinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started

Get In Touch

For more information on leronlimab, our science, or our new developments, please reach out to us using the link provided.

Ask a Question